Market research
OCGN Ocugen Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 461M
- P/E ratio
- Not available
- Analyst target
- 12.1667
- Dividend yield
- Not available
- Beta
- 2.2
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US67577C1053
- Market cap
- 461M
- P/E ratio
- Not available
- Analyst target
- 12.1667
- Dividend yield
- Not available
- Beta
- 2.2
About
About Ocugen Inc
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is involved in the development of OCU200, a novel recombinant fusion protein for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the OCGN discussion.
5 years, 4 months ago
Ocugen, Inc is currently in a long term uptrend where the price is trading 43.6% above its 200 day moving average.
From a valuation standpoint, the stock is 1148.5% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 16722.2.
Ocugen, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 130.6% to $-4M since the same quarter in the previous year.
Finally, its free cash flow grew by 48.5% to $-5M since the same quarter in the previous year.
Based on the above factors, Ocugen, Inc gets an overall score of 2/5.